Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • Wednesday
Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 04/15/24
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsGlobeNewsWire • 04/08/24
Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers SymposiumGlobeNewsWire • 02/29/24
Cue Biopharma to Present at the JMP Securities Hematology and Oncology SummitGlobeNewsWire • 11/22/23
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in NovemberGlobeNewsWire • 11/07/23
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023GlobeNewsWire • 11/03/23
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingGlobeNewsWire • 09/27/23
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®GlobeNewsWire • 09/26/23
Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/09/23
Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 05/25/23
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/09/23
Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/09/23
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences ConferenceGlobeNewsWire • 05/08/23
Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of DirectorsGlobeNewsWire • 04/12/23